Search 

Etcembly’s vision is to decode immune repertoires for health and disease.

The TCR repertoire holds the answers to therapeutics and biomarker information, and Etcembly is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics across all patient groups, globally.

We are pushing the frontiers to explore the intersection between immunology and machine learning.

Evgen is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation. 

There is a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods. 

Evgen exploits sulforaphane’s activity in three distinct disease-relevant cellular pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases which are characterised by excessive oxidative stress, and inflammation and inhibition of SHP2, a target that has relevance in a number of solid tumours and haematological cancers.

Ingenza is a biotechnology company specialising in the design, development and manufacture of diverse, high-value industrial products and therapeutic-proteins. We exploit synergies between synthetic and evolutionary biology, providing next generation microbial and mammalian manufacturing platforms.

What makes Ingenza unique?

Dynamic teamwork forged from full integration between the in-house molecular biology, fermentation and chemistry teams, boosted by close ties to UK universities, provides the perfect skillsets to expertly guide you through your project. We can support you at any stage of development, from proof of concept to scaled-up manufacture under GMP conditions.

Combining the old and the new

Ingenza’s ethos is all about combining the best tried-and-tested traditional methods, the latest breakthroughs and technologies, and a healthy dose of experience and expertise, to bring refreshing innovation to the development of sustainable and cost-competitive biotechnology.

Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.

LSX is a growing influential community of senior life science decision makers, and are a catalyst for dialogue, debate and deal making to help lead growth in healthcare investment and the building of billion pound healthcare businesses. LSX is determined to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare.

Their community helps catalyse early stage innovation through peer-to-peer education and knowledge sharing, networking, partnering and deal making to champion the most innovative and exciting ideas. LSX brings deals to life.